Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007

Journal of Viral Hepatitis

Volumn 18, Issue 5, 2011, Pages 316-324

  Vellozzi, C ^a,d   Buchacz, K ^a   Baker, R ^b   Spradling, P R ^a   Richardson, J ^b   Moorman, A ^a   Tedaldi, E ^c   Durham, M ^a   Ward, J ^a   Brooks, J T ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CERNER CORPORATION   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HAART; HCV treatment; hepatitis C; HIV HCV; HIV infection; interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTION; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 79953870639     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01299.x     Document Type: Article

References (50)

1. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16 (12): 1663-1671. (Pubitemid 34921112)
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338 (13): 853-860. (Pubitemid 28135961)
3. Weber R, for the Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus-The D: A: D study. Arch Intern Med 2006; 166 (15): 1632-1641. (Pubitemid 44232373)
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32 (3): 492-497. (Pubitemid 32173638)
5. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34 (1): 121-130. (Pubitemid 40347381)
6. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Finelli L, Bell BP, Brooks JT,. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr 2010; 53: 388-396.
7. Sulkowski MS, Thomas DL,. Hepatitis C in the HIV-infected person. Ann Inter Med 2003; 138 (3): 197-207. (Pubitemid 36231625)
8. Sherman KE, Rouster SD, Chung RT, Rajicic N,. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis 2002; 34 (6): 831-837. (Pubitemid 34194855)
9. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36 (3): 363-367. (Pubitemid 36169673)
10. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42 (5): 615-624.
11. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30 (4): 1054-1058. (Pubitemid 29458296)
12. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36 (4): 491-498. (Pubitemid 36241318)
13. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-Related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33 (2): 240-247. (Pubitemid 32643340)
14. SanchezQuijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14 (11): 949-953.
15. Burgess J, Davey V, Raab C, et al. Management and treatment of hepatitis C virus infection in HIV-infected adults: Recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 2005; 100 (10): 2338-2354.
16. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21 (9): 1073-1089. (Pubitemid 46763278)
17. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK,. Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the national institutes of health, and the HIV medicine association/infectious diseases society of America. Clin Infect Dis 2005; 40: S131-S235. (Pubitemid 40365525)
18. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep 1999; 48 (RR10): 1-59, 61-6.
19. FDA Approves Pegasys in Combination With Copegus (ribavirin) for HCV Treatment. 2002 Available at: http://www.natap.org/2002/Dec/120402-1.htm (accessed 2 March 2009).
20. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292 (23): 2839-2848. (Pubitemid 39628231)
21. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351 (5): 451-459. (Pubitemid 38988594)
22. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18 (13): F27-F36. (Pubitemid 39179626)
23. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351 (5): 438-450. (Pubitemid 38988593)
24. Care and Treatment for Hepatitis C and HIV Coinfection. Available at: http://hab.hrsa.gov/tools/coinfection/hcvtreatment.html (accessed 2 March 2009).
25. Centers of Disease Control and prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53: 49-53.
26. Butt AA, Mcginnis KMS,. HCV Treatment Eligibility in ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans). 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) American Society of Microbiology. Washington, DC, 2008.
27. Kramer JR, Kanwal F, Giordano TP,. Patient, Provider, and Facility Characteristics of HCV Antiviral Treatment Among US Veterans with HCV-HIV Coinfection. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008) American Association for the Study of Liver Diseases. San Francisco, California, 2008.
28. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK,. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther 2006; 24 (4): 585-591. (Pubitemid 44127839)
29. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR,. Hepatitis C virus infection in San Francisco's HIV-infected urban poor-High prevalence but low treatment rates. J Gen Intern Med 2004; 19 (4): 357-365. (Pubitemid 38530507)
30. Mocroft A, Rockstroh J, Soriano V, et al. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006; 38 (11-12): 1092-1097. (Pubitemid 44869287)
31. Zinkernagel AS, von Wyl V, Ledergerber B, et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 2006; 11 (2): 131-142.
32. Fleming CA, Tumilty S, Murray JE, Nunes D,. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005; 40: S349-S354. (Pubitemid 40490224)
33. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20 (18): 2361-2369. (Pubitemid 44789539)
34. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK,. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-389. (Pubitemid 46579770)
35. Manos M, Shvachko V, Zhoo W, Murphy RC,. Determinants of HCV antiviral treatment in a managed care setting. Hepatology 2008; 48 (4): 1252.
36. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon alfa-2a and ribavirin in African American and Caucasian patients with chronic hepatitis C, genotype 1. Hepatology 2005; 42 (4): 275A-276A.
37. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ,. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117 (3): 163-168. (Pubitemid 39055867)
38. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR,. Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1. Hepatology 2004; 39 (6): 1702-1708. (Pubitemid 38702672)
39. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47 (1): 36-49. (Pubitemid 351619367)
40. Soriano V, Puoti M, Sulkowski M, et al., Care of patients with hepatitis C and HIV co-infection. AIDS 2004; 18 (1): 1-12. (Pubitemid 38402312)
41. Castera L, Foucher J, Bertet J, Couzigou P, De Ledinghen V,. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 2006; 43 (2): 373-374.
42. Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIV-positive patients with hepatitis C virus-Role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr 2006; 41 (1): 63-67. (Pubitemid 41786021)
43. Okanoue T, Makiyama A, Nakayama M, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005; 43 (4): 599-605. (Pubitemid 41253226)
44. Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4): 84-91.
45. Cacoub P, Halfon P, Rosenthal E, et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol 2008; 48 (1): 35-42. (Pubitemid 350191985)
46. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17 (5): 721-725. (Pubitemid 36521078)
47. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43 (6): 1317-1325. (Pubitemid 43980111)
48. Castera L, Vergniol J, Foucher J, et al., Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2): 343-350. (Pubitemid 40439195)
49. Martin-Carbonero L, Sanchez-Somolinos M, Garcia-Samaniego J, et al. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. J Viral Hepat 2006; 13 (12): 851-857. (Pubitemid 44748291)
50. Soriano V,. Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. J Hepatol 2006; 44 (1 Suppl): S44-S48. (Pubitemid 43053873)